⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Official Title: A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study ID: NCT01196741

Study Description

Brief Summary: The purpose of this study is to investigate whether the addition of the Src inhibitor saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus placebo, in patients with relapsed platinum-resistant ovarian cancer. The trial will also determine toxicity and ascertain whether the combination of paclitaxel plus saracatinib should proceed to a phase III trial.

Detailed Description: A multicentre, randomised, double-blind, placebo-controlled Phase II trial will be conducted. The overall aim of the trial is to investigate whether the addition of saracatinib to weekly paclitaxel improves efficacy, as measured by progression free survival, compared with paclitaxel plus placebo. The trial will also determine toxicity and ascertain whether the combination of paclitaxel plus saracatinib should proceed to a phase III trial. The toxicity data from Study NCT00610714 (D8180C00015) suggests that a small number of patients could experience febrile neutropaenia during their first chemotherapy cycle. To combat this, saracatinib (175 mg OD)/matched placebo will begin 1 week prior to commencement of chemotherapy, and be given continuously until progression. All patients will receive cycles of weekly paclitaxel chemotherapy. One cycle will consist of weekly paclitaxel (80 mg/m2) for 6 weeks followed by 2 weeks rest. If there is evidence of on-going response after 4 cycles, 3 further cycles of saracatinib/placebo plus weekly paclitaxel will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom

St Bartholomew's Hospital, London, Greater London, United Kingdom

University College London Hospital, London, Greater London, United Kingdom

Guy's Hospital, London, Greater London, United Kingdom

The Royal Mardsen Hospital, London, Greater London, United Kingdom

The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

Mount Vernon Hospital, Rickmansworth, Middlesex, United Kingdom

The Churchill Hospital, Oxford, Oxfordshire, United Kingdom

Queen's Hospital, Burton upon Trent, Staffordshire, United Kingdom

Royal Marsden Hospital, Sutton, Surrey, United Kingdom

St James's University Hospital, Leeds, Yorkshire, United Kingdom

Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom

Contact Details

Name: Iain McNeish

Affiliation: Barts and the London NHS Trust

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: